Breast cancer with lymph node metastases were in general associated with lower levels of the CSC genes ALDH1A3 and CD44, pluripotency markers POU5F1 and NEAT1, EMT marker SLUG, and drug resistance associated gene ERBB2, after DOX treatment. This evidence concerns the gene ALDH1A3 and metastatic malignant neoplasm in the lymph nodes.